Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
bluebird bio, Inc. BLUE
$4.33
-$0.39 (-8.95%)
На 18:00, 12 мая 2023
+226.10%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
511170315.00000000
-
week52high
8.58
-
week52low
2.78
-
Revenue
3597000
-
P/E TTM
-1
-
Beta
0.91591600
-
EPS
-4.03000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Sell | Sell | 19 авг 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 18 авг 2022 г. |
| Barclays | Equal-Weight | Underweight | 05 авг 2022 г. |
| Raymond James | Outperform | Market Perform | 02 авг 2022 г. |
| Goldman Sachs | Sell | Sell | 24 мая 2022 г. |
| Raymond James | Outperform | Outperform | 20 сент 2022 г. |
| RBC Capital | Sector Perform | Sector Perform | 08 ноя 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 06 янв 2023 г. |
| Morgan Stanley | Underweight | Underweight | 24 янв 2023 г. |
| SVB Leerink | Market Perform | Market Perform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Vittiglio Joseph | A | 100000 | 100000 | 01 февр 2023 г. |
| Vittiglio Joseph | A | 50000 | 50000 | 01 февр 2023 г. |
| Obenshain Andrew | D | 241270 | 1420 | 01 февр 2023 г. |
| Colvin Richard A | D | 73078 | 1153 | 01 февр 2023 г. |
| Klima Thomas J | D | 82179 | 2260 | 01 февр 2023 г. |
| Leschly Nick | D | 280149 | 4290 | 11 янв 2023 г. |
| Colvin Richard A | D | 74231 | 557 | 11 янв 2023 г. |
| Obenshain Andrew | D | 242690 | 3178 | 11 янв 2023 г. |
| Krawtschuk Christopher | A | 100000 | 100000 | 01 дек 2022 г. |
| Krawtschuk Christopher | A | 50000 | 50000 | 01 дек 2022 г. |
Новостная лента
bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona
Zacks Investment Research
10 мая 2023 г. в 13:41
bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.
Bluebird Bio (BLUE) Q1 Earnings Surpass Estimates
Zacks Investment Research
09 мая 2023 г. в 09:57
Bluebird Bio (BLUE) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.54 per share. This compares to loss of $1.66 per share a year ago.
May MDA Breakout Stocks/ETFs Week 18: High-Frequency Gainers To Give You An Edge
Seeking Alpha
30 апр 2023 г. в 06:11
Two new Breakout Stocks for Week 18 with better than 10% short-term upside, ETF updates and two Dow 30 Picks. Average cumulative returns for 2023 are +58.9% YTD. Negative MG Signal continues, but peak gains were in ANNX +10.2% and ONON +5%. The Active ETF portfolio continues with YTD gains at +13.0%.
Why Is Bluebird Bio (BLUE) Stock Up 17% Today?
InvestorPlace
28 апр 2023 г. в 14:39
Curative gene therapy specialist Bluebird Bio (NASDAQ: BLUE ) popped up strongly amid a broadly positive Friday on Wall Street. Primarily, the enthusiasm centers on JPMorgan Chase's Eric Joseph, who initiated coverage of BLUE stock with an “overweight” rating.
Why Is Bluebird (BLUE) Up 17.2% Since Last Earnings Report?
Zacks Investment Research
28 апр 2023 г. в 12:56
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?